News Center

Home page

Peak Report

News reports

Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-1

Release time:

2020-08-05

Stock Abbreviations: Jianfeng Group Stock Code: 600 668 Announcement No.: Pro 2013- 021

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Zhejiang Jianfeng Group Co., Ltd.

201 3 Corporate Bonds (Phase I)

Listing Announcement

Securities Abbreviation: 13 Peak 01

Securities Code: 122227

Total Issue: RMB 3 billion Yuan

Listing Time: 2013 7 2

Listing place: shanghai Stock Exchange

Sponsor (Lead Underwriter) / Listing Recommender

( Registered Address: hangzhou Hangzhou Hangzhou Hangzhou Road 1 )

2013 7 January

Section I Introduction

Important Tips

Zhejiang Jianfeng Group Co., Ltd. (the following is called "Jianfeng Group ", "Company" or "Issuer") Members of the Board of Directors have approved this Listing Announcement, guarantee that there are no false records, misleading Chen or material omissions, and assume individual and joint legal responsibility for its truthfulness, accuracy and completeness.

The approval of the Shanghai Stock Exchange (hereinafter referred to as the "SSE" ) for the listing of corporate bonds does not indicate a substantive judgment or guarantee of the investment value of the bonds or the return of investors. Investors who purchase bonds are responsible for the investment risks arising from changes in the company's operations and earnings. 117.

has been comprehensively evaluated by

of United Credit Rating Co., Ltd. (hereinafter referred to as "United Rating " ). Jianfeng Group current corporate bonds Credit rating is AA + , and the main credit rating is AA ; Before the listing of bonds, the net assets of the issuer at the end of the latest period were ,164,643.81 .38 million yuan (total owner's equity of in the consolidated statement as of 2012 , 142# December , March 31 ) , and the asset-liability ratio of consolidated statement caliber was 40.74 (the asset-liability ratio of parent company caliber was 25.77 ); before the listing of the current bonds, the average annual distributable profit realized by the issuer in the last three fiscal years was 18,836.85 .56 million yuan (average of the net profit attributable to the owners of the parent company in the consolidated statements of 20 10 , 2011 and 201 2 #), expected not less than 1.5 times the one-year interest on this issue bonds. Section II Issuer Profile

1. Issuer Legal Name

Chinese Name: Zhejiang Jianfeng Group Co., Ltd.

English Name: ZHEJIANG JIANFENG GROUP CO.,LTD

2. Issuer Registered Address and Office Address

Registered Address: No. 88 193, Wujiang East Road, Jinhua City, Zhejiang Province

Office Address: No. 88 199, Wujiang East Road, Jinhua City, Zhejiang Province

3. Issuer Registered Capital

Registered Capital: RMB 344,083,828.00 RMB

4. Issuer Legal Representative

Legal Representative: Jiang Xiaomeng

5. Issuer Basic Information

(I) Issuer Business Scope

Issuer's business scope is:

cement, cement concrete, prefabricated components, common machinery, auxiliary materials, communication equipment, caulking materials, instruments and meters, paper bags manufacturing and sales, import and export business (see approval of the Foreign Trade Office for details), and industrial investment.

Main Business of (II) Issuers

According to "Guidelines for Industry Classification of Listed Companies (2012

Revision)" (CSRC Announcement [

2012 ]

), issuers belong to "Non-metallic Mineral Products Industry" and "Pharmaceutical Manufacturing Industry". The issuer's main business is cement manufacturing and sales, pharmaceutical manufacturing and sales, pharmaceutical commercial circulation. cement business is carried out in daye peak and Yunnan peak system, the issuer's holding subsidiaries. the issuer has been engaged in this business since was listed in 1993 , accounting for about 40% of the issuer's main business income. this business is mainly engaged in the production and sales of cement and cement clinker.

pharmaceutical business is carried out within the peak pharmaceutical system of the issuer's holding subsidiary, accounting for about 50% of the issuer's main business income . The business mainly covers two categories: pharmaceutical industry and pharmaceutical commerce. Company

2010

, 2011 and 2012

, with operating income of

132, .09 .63 million yuan, 164, .88 .65 million yuan and 164,909.55 .67 million yuan respectively, operating income stable growth ; the proportion of main business income to operating income is above 99% . The composition of the company's main business income in the past three years is as follows: units: ten thousand yuan

industry name

2012 degree	2011 year		2010 year		amount
2012 degree	Proportion	Amount	Proportion	Amount	Proportion	Cement Industry
63,012.93	38.38%	72,736.61	44.45%	51,038.47	38.83%	Pharmaceutical Industry
82,785.43	50.42%	76,543.88	46.77%	65,262.72	49.66%	other industries
18,379.87	11.20%	14,366.78	8.78%

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页